We are live on ! Find out more

Halozyme

HALO

Market cap $12.3B

108.31 USD

-1.88

1.71%

At close Updated Sep 8, 4:00 PM EDT

Pre-market

After hours

108.31

0.00

0%

1 day

-1.71%

5 days

0.8%

1 month

5.54%

3 months

53.13%

6 months

58.95%

Year to date

54.05%

1 year

42.79%

5 years

157.57%

10 years

910.35%

About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Employees: 423

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 72.7%

Neutral 27.3%

Negative 0%

Zacks Investment Research

4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026

Four GARP stocks combine discounted PEG ratios with strong growth prospects, offering investors value and potential in 2026.

4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026

Halozyme to Participate at Upcoming Investor Conferences

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.

Halozyme to Participate at Upcoming Investor Conferences

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

For investors seeking opportunities outside the AI trade, healthcare stocks can offer diversification without sacrificing exposure to growth. S&P 500 healthcare earnings are projected to rise by 22% YoY in 2027, the second-highest estimated growth rate among the eleven sectors, topped only by technology. According to JPMorgan analysts, at a time when many investors remain highly concentrated in the AI theme, healthcare offers a rare combo of durable growth, tech-like margins, and value.

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

Halozyme: The Market May Be Underpricing The Second Growth Wave

Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.

Halozyme: The Market May Be Underpricing The Second Growth Wave

Zacks Investment Research

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice

Zacks Investment Research

5 Value Stocks to Buy Right Now as Inflation Remains Sticky

HLF, HMC, MPC, HALO and GNW screen as high-earnings-yield value picks as inflation stays elevated.

5 Value Stocks to Buy Right Now as Inflation Remains Sticky

Zacks Investment Research

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

See News Rankings

Price charts implemented using Lightweight Charts™